oral glp 1 meds Comparing Ozempic, Wegovy and Other GLP-1 Drugs crave less Oral GLP-1 Orforglipron Is Approved

Thats slower than the 15% body weight loss seen with standard semaglutide in the STEP trials

Gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation are common across GLP-1 therapies

Claustre, J., Brechet, S., Plaisancie, P., Chayvialle, J

The FDA approved once-daily oral semaglutide (Wegovy) at 25 mg on 22 December 2025, making it the first oral GLP-1 approved specifically for chronic weight management in the US

Remember: Use the TRICARE Formulary Search Tool to check costs and coverage requirements

It could be because you didnt meet the criteria, but it could also be because your employer has opted out of weight loss benefits